NCT03357224 2024-02-22
PARCT
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
Clinical Trials
3 trialsNCT02659384 2023-03-14
Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT03818997 2020-02-05
DYNAMIC
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Withdrawn